Thursday 7 May, 2026
Introduction/Objectives: Olanzapine is a second-generation antipsychotic drug for the treatment of schizophrenia. Oral administration requires daily dosing, often limiting long-term…
Read morePoster: Drug/Disease Modelling - CNS
A MINIMAL MECHANISTIC QSP-READY MODEL TO BRIDGE AGGREPHAGY AND MTOR SIGNALING IN ALS
Thursday 7 May, 2026
Introduction: Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease marked by motoneuron loss and progressive muscle atrophy. Familial ALS…
Read moreEXPOSURE-RESPONSE RELATIONSHIP OF ONCE-MONTHLY SUBCUTANEOUS OLANZAPINE (TV-44749) FOR THE CLINICAL GLOBAL IMPRESSION-SEVERITY SCALE IN PATIENTS WITH SCHIZOPHRENIA
Thursday 7 May, 2026
Introduction/Objectives: Olanzapine is a second-generation antipsychotic drug available in oral, intramuscular (IM) immediate release, and IM long-acting injectable (LAI) formulations….
Read morePopulation Pharmacokinetic-Pharmacodynamic Modelling of Ciprofol in Chinese Elderly Patients Undergoing Orthopedic Surgery
Thursday 7 May, 2026
Introduction: Ciprofol is a novel γ-aminobutyric acid type A (GABA A) receptor agonist with 4–5 fold greater potency than propofol…
Read morePopPK and PKPD Modeling of Oral NLRP3 Inhibitor Supporting Dose Simulation in Parkinson’s Disease
Thursday 7 May, 2026
Objectives: The release of pro-inflammatory cytokines, including interleukin (IL)-18 and IL-1β, is potentially driven by the Nucleotide-binding oligomerization domain, leucine-rich…
Read moreAn Item Response Theory-Based Comparison of Multiple Versions of SARA Rating Assessment of Degenerative Ataxia in a SCA3 Cohort
Thursday 7 May, 2026
Background: Spinocerebellar Ataxia (SCA) is a heterogeneous group of rare autosomal-dominant progressive diseases that affect gait, balance, and limb coordination…
Read morePOPULATION PHARMACOKINETIC MODELLING OF BEDAQUILINE IN CENTRAL NERVOUS SYSTEM TISSUES IN A RABBIT MODEL OF TUBERCULOUS MENINGITIS
Thursday 7 May, 2026
Objectives: Tuberculous meningitis (TBM) is the most severe form of tuberculosis (TB) and is associated with high mortality and long-term…
Read moreA quantitative systems pharmacology (QSP) model of neuroinflammation in Mild Cognitive Impairment and early Alzheimer’s Disease dementia
Thursday 7 May, 2026
Objectives: Neuroinflammation plays a critical role in Alzheimer’s Disease (AD) pathogenesis, with multiple therapeutic targets being investigated in the clinic….
Read morePOPULATION PKPD AND EXPOSURE–RESPONSE ANALYSIS OF EPLONTERSEN SUPPORTS 45 MG SC Q4W WITHOUT DOSE ADJUSTMENT IN HEREDITARY TRANSTHYRETIN-MEDIATED POLYNEUROPATHY
Thursday 7 May, 2026
Objectives To characterize the population PK (popPK), PKPD (popPKPD), and exposure–response (ER) relationships for efficacy and safety of eplontersen, supporting…
Read moreUse of a Clinical utility index to assess the opioid sparring effect between morphine and pregabalin and as aid in dose optimization.
Thursday 7 May, 2026
Introduction: Chronic pain is a major burden for patients and is highly prevalent. In Europe and the US 21% and…
Read more